secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001437749-23-024064
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 3.03, 4.01, 5.01, 5.02, 5.03, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed (fka Diffusion) completes reverse merger with EIP Pharma, begins trading under CRVO
--------------------------------------------------------------------------------

- Merger closed August 16, 2023; EIP Pharma becomes wholly owned sub; 5.67M shares issued to former EIP holders.
- EIP equityholders own ~77.95% of combined company; Diffusion holders ~22.05% on fully-diluted basis.
- Company renamed CervoMed Inc.; common stock trades on Nasdaq under CRVO (post 1-for-1.5 reverse split).
- New CEO John Alam (previously EIP CEO); CFO William Tanner; board includes 5 EIP designees.
- Company now a DLB-focused biopharma; lead candidate neflamapimod in Phase 2b; auditor changed to RSM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/0001437749-23-024064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/dffn20230816_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-024064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer